[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-arterial-diseasepad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-arterial-diseasepad":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,73,101,126,152,180,209,229,253,275],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643648","ankle-brachial-index-changes-post-exercise-and-its-effects-on-patient-centered-outcomes-and-gait-100643648",false,"NCT07637396","Ankle-Brachial Index Changes Post Exercise and Its Effects on Patient-Centered Outcomes and Gait","Exercise-Induced Ankle-Brachial Index Dynamics as a Predictive Marker in Peripheral Arterial Disease","ExerciseABI","Inclusion Criteria\n\n* individuals over 65 years of age\n* individuals aged 50-64 with a risk factor for atherosclerosis including diabetes mellitus, history of smoking, hyperlipidemia, hypertension, or family history of peripheral arterial disease (PAD)\n* individuals aged 18-50 with diabetes mellitus and one additional risk factor for atherosclerosis as noted above, or\n* individuals with known atherosclerotic disease in another vascular bed including the coronary, carotid, subclavian, renal, or mesenteric artery stenosis, and individuals with known PAD\n\nExclusion Criteria\n\n* contraindications to brachial and\u002For ankle pressure measurement including history of deep vein thrombosis\n* lymphedema of the arms or legs\n* history of mastectomy or current leg ulceration preventing placement of a blood pressure cuff around the lower leg\n* an inability to lie in a supine position for 15 min\n* self-reported inability to walk for 6 minutes\n* severe cardiac or pulmonary disease limiting exercise\n* inability to obtain a Dopplerable pulse\n* noncompressible arteries (ABI \\>1.4)\n* those unable to consent",true,"ALL","18 Years",{"count":21,"type":22},85,"ESTIMATED","OBSERVATIONAL","The goal of this observational study or clinical trial is to investigate how exercise can affect different areas of a person's life, especially those people with vascular disease. This is important because exercise can be beneficial for people with vascular disease. The study could include any of the following: those aged 65 years of age and older, between the ages of 50-64 who smokes, has diabetes, high blood pressure, high cholesterol, or has a family member with vascular disease, between the ages of 18-49 with diabetes and one other factor listed above, or those with vascular disease. The main question\\[s\\] it aims to answer is if exercise testing can better predict vascular disease.\n\nThe following research questions will be addressed in this study:\n\n1. Does baseline ABI influence the magnitude and recovery trajectory of ABI following an acute bout of exercise across a spectrum of vascular function?\n2. What association does exercise-induced ABI changes have on patient-reported outcomes of quality of life and intermittent claudication?\n3. Do functional outcomes of gait speed, time to claudication, gait variables related to rest breaks in 6MWT, and walking distance predict the magnitude of exercise-induced ABI reduction?\n\nParticipants will :\n\n* complete various questionnaires and a routine screening for vascular disease \\*walk for 6 minutes at your own pace\n* additional vascular screening tests will be performed.",[26],"Peripheral Arterial Disease(PAD)",[28,29,30],"peripheral arterial disease","ankle brachial index","doppler ultrasound","NOT_YET_RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-09","ACTUAL",{"date":37,"type":22},"2026-06",{"date":39,"type":22},"2028-01",{"name":41,"class":42},"Louisiana State University Health Sciences Center Shreveport","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100591350","intravascular-ultrasound-for-peripheral-artery-disease-revascularization-100591350","NCT06979284","Intravascular Ultrasound for Peripheral Artery Disease Revascularization","Intravascular Ultrasound for Peripheral Artery Disease Revascularization: The CLARITY Randomized Controlled Trial","CLARITY","Inclusion Criteria:\n\n1. Patients presenting with lower extremity PAD manifesting as CLTI:\n\n   a. CLTI is defined as ischemic rest foot pain, nonhealing wounds, or gangrene present for at least two weeks and that is attributable to objectively proven arterial occlusive disease, compatible with Rutherford class 4, 5 or 6, with the following supporting hemodynamic criteria1: i. For ischemic rest pain (Rutherford category 4): Ankle systolic pressure \\\u003C 40mmHg, toe pressure \\\u003C 30mmHg, or flat-line transtarsal pulse volume recording, OR ii. For tissue loss (Rutherford category 5, 6): Ankle systolic pressure \\\u003C 60 mmHg, toe pressure of \\\u003C 40mmHg, or flat-line transtarsal volume recording, AND\n2. Scheduled to undergo percutaneous revascularization, AND\n3. Informed consent\n4. Imaging evidence of an obstructive or occluded lesion (\\> 70%) in the infraiguinal circulation (e.g. femoral, popliteal, or infrapopliteal circulation) using angiography, ultrasound, computed tomography, or magnetic resonance imaging.\n5. An infrapopliteal lesion must be located in the proximal 2\u002F3 of native infrapopliteal vessels, with a vessel diameter of \\> 2.5mm by investigator visual assessment.\n6. The distal margin of the most distal target lesion must be located \\> 10 cm proximal to the proximal margin on the ankle mortise. The vessel segment distal to the most distal target lesion must be patent all the way to the ankle, with no obstructive lesion (\\>50% stenosis).\n\nExclusion Criteria:\n\n1. The presence of anatomic or comorbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the potential participant's ability to participate in the trial or to comply with the follow-up requirements.\n2. The presence of any medical conditions precluding percutaneous revascularization\n3. The subject has previously had or requires surgical revascularization involving the vessel containing the target lesion of the ipsilateral extremity.\n4. The subject is bedridden or unable to walk (with assistance is acceptable).\n5. Life expectancy \\\u003C 12 months\n6. Age \\\u003C 18 years\n7. Active vasculitis, Buerger's disease, or acute limb-threatening ischemia\n8. Planned above-ankle amputation of the index limb within four weeks of the index procedure.\n9. Obstructive supra-inguinal \"inflow\" (\\>70% stenosis) which is not planned to be treated during index procedure or within 30 days of the index procedure.\n10. The subject has had any amputation to the ipsilateral extremity other than the toe or forefoot, or the subject has had a major amputation to the contralateral extremity \\\u003C 1 year before the index procedure and is not independently walking.\n11. Extensive tissue loss that is salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputations.\n\n    1. Osteomyelitis that extends proximal to the metatarsal heads\n    2. Gangrene involving the plantar skin of the forefoot, midfoot or heel\n    3. Deep ulcer or large shallow ulcer (\\> 3 cm) involving the plantar skin of the f forefoot, midfoot, or heel\n    4. Full-thickness heel ulcer\n    5. Any wound with calcaneal bone involvement\n    6. Wounds that would require flap coverage or complex wound management for large soft tissue defect\n    7. Full-thickness wounds on the dorsum of the foot with exposed tendon or bone.",{"count":53,"type":22},772,"INTERVENTIONAL",[56],"NA","The purpose of this study is to determine if IVUS use, as compared to angiography alone, prevent major adverse limb events (MALE) or binary restenosis (a greater than 50% re-narrowing of the treated artery) in adult patients who have CLTI and are undergoing percutaneous revascularization.",[26,59,60,61,62],"Chronic Limb Threatening Ischemia","Intravascular Ultrasound","Major Adverse Limb Events","Restenosis","RECRUITING",{"date":65,"type":35},"2026-06-08",{"date":67,"type":35},"2025-12-05",{"date":69,"type":22},"2030-10",{"name":71,"class":42},"Hamilton Health Sciences Corporation",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":54,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100631325","lymphatic-injury-visualization-in-vascular-surgery-100631325","NCT07499206","Lymphatic Injury Visualization in Vascular Surgery","Visualization and Treatment of Lymphatic Injury During Vascular Surgery Procedures in the Groin: A Pilot Study","LymphFistula-P","Inclusion Criteria:\n\n* adult patients undergoing vascular surgery procedures in the groin\n* signed informed consent for study participation\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* prior groin surgery\n* infected surgical site in the groin\n* necessity for further incisions (e.g. bypass surgery)\n* incapability of judgement or consent","100 Years",{"count":83,"type":22},60,[56],"This study aims to assess a simple intervention: Visualization of lymphatic injury + treatment (in case of detection). This will generate data on the incidence of intraoperative lymphatic injury and the effect of treatment. This data will then hopefully enable a multi-center RCT to generate high level evidence on this matter.",[87,26,88,89,90,91],"Vascular Surgical Procedure","Acute Ischemia","Hemmorhage","Aneurysm","Pseudoaneurysm","2026-03-23",{"date":94,"type":35},"2026-03-30",{"date":96,"type":22},"2026-04",{"date":98,"type":22},"2027-04",{"name":100,"class":42},"University Hospital, Basel, Switzerland",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100605050","vascular-complications-in-patients-undergoing-peripheral-revascularization-and-taking-sglt-2-inhibitors-100605050","NCT07157475","Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors","Ocena powikłań Naczyniowych u pacjentów Poddanych Rewaskularyzacji Obwodowej: wpływ inhibitorów SGLT-2 The Assessment of Vascular Complications in Patients Undergoing Peripheral Revascularization: The Impact of SGLT-2 Inhibitors","Inclusion Criteria:\n\n* Peripheral vascular procedure ( Conventional surgical procedure or minimally invasive procedure) due to acute or chronic ischemia\n* Use of SGLT2 inhibitors (applies only to the group exposed to flozins) for at least 3 months prior to the vascular procedure (the indication for initiating the drug is irrelevant: chronic kidney disease \\[CKD\\] \u002F cardiac reasons \u002F diabetes), or immediately after the vascular procedure\n* Ability to determine the patient's outcomes within a minimum of 30 days up to 1 year following the vascular procedure\n\nExclusion Criteria:\n\n* Vascular injury as the reason for the procedure\n* Amputation due to causes other than ischemia (e.g., cancer, neuropathy, trauma without coexisting ischemia)\n* Planned revascularization procedure other than for the lower limbs at the time of hospital discharge (e.g., coronary or carotid arteries)\n* Planned ischemia-related amputation or reoperation of the operated limb at the time of hospital discharge\n* Planned other major surgical procedure with high cardiovascular risk at the time of hospital discharge",{"count":109,"type":22},300,"The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures. Patients who are at least one year post-procedure will be contacted by phone and asked whether any cardiovascular complications occurred during that period, specifically major adverse cardiovascular events (MACE) or major adverse limb events (MALE), and whether they had been taking sodium-glucose co-transporter 2 inhibitors (SGLT2-i, \"flozins\") during the year following the procedure. The results from the group of pts who, for any reason, received SGLT2-i treatment after the vascular procedure (including those who had initiated treatment before surgery) will be compared to the results from the group of patients who did not receive such treatment, with regard to the occurrence of the aforementioned complications.",[26],[113,114,28,115,116,117],"flozins","SGLT2i","revascularisation","MACE","MALE","2026-03-18",{"date":92,"type":35},{"date":121,"type":35},"2025-07-01",{"date":123,"type":22},"2026-12-31",{"name":125,"class":42},"Wroclaw Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":18,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":54,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":72},"100594227","real-world-registry-of-the-rotarextm-rotational-excisional-atherectomy-system-xtract-registry-100594227","NCT07016698","Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)","A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)","Inclusion Criteria:\n\n1. Subject or legally authorized representative provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the IRB for the site.\n2. Subject is ≥22 years old at the time of signing the informed consent.\n3. Subject must have a lesion(s) in their infra-inguinal peripheral arteries that can be treated with the RotarexTM Rotational Excisional Atherectomy System according to Instructions For Use (IFU).\n4. Rutherford 2-5 for chronic limb ischemia and Rutherford I to IIb for acute limb ischemia.\n5. Target lesion can be crossed intra-luminally by guidewire.\n6. At least one patent native outflow artery to the foot, free from significant stenosis(≥50% stenosis as confirmed by angiography) (ChLI Cohort only, not applicable to ALI Cohort).\n\nExclusion Criteria:\n\n1. Subject is unable or unwilling to comply with follow-up procedures and visits.\n2. Subject has a target lesion in a vessel with less than 3 mm in diameter.\n3. Subject is participating in another device or drug clinical trial that interferes with this protocol and confounds results.\n4. Treatment plan includes use of a thrombectomy and\u002For atherectomy device other than RotarexTM Rotational Excisional Atherectomy System.\n5. Life expectancy is below 1 year.\n6. Pregnant, planning to become pregnant during the course of the study or nursing a child.","22 Years",{"count":135,"type":22},600,[56],"The XTRACT Registry is a prospective, single arm multicenter study on the use of on the Rotarex(TM) Rotational Excisional Atherectomy System.",[26],[140,141],"Rotarex","PAD","2025-12-12",{"date":144,"type":35},"2025-12-17",{"date":146,"type":35},"2025-09-29",{"date":148,"type":22},"2029-05-31",{"name":150,"class":151},"C. R. Bard","INDUSTRY",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":18,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":54,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100600466","assessment-of-revascularization-in-plantar-foot-of-diabetic-patients-pre-and-post-angioplasty-using-spatial-frequency-domain-imaging-100600466","NCT07097857","Assessment of Revascularization in Plantar Foot of Diabetic Patients Pre and Post Angioplasty Using Spatial Frequency Domain Imaging","Assessment of Revascularization in Plantar Foot of Diabetic Mellitus Patients Pre and Post Angioplasty Using Spatial Frequency Domain Imaging","Inclusion Criteria:\n\n* Patients of age 21 years and above with diabetes and undergoing lower limb arterial angioplasty\n* Willingness to participate in the study and undergo foot physiological assessments using SFDI\n\nExclusion Criteria:\n\n* Mentally incompetent, younger than 21 years of age, prisoners, pregnant or breastfeeding women\n* Patients unable to provide informed consent\n* Any medical condition which makes the candidate an inappropriate subject for study participation, in the investigator's judgment","21 Years","99 Years",{"count":162,"type":22},15,[56],"To explore the usefulness of SFDI in the assessment of revascularization pre and post intervention",[26,166],"Imaging Evaluation",[168,169,170],"Spatial Frequency Domain Imaging","Peripheral Arterial Disease","Non-invasive imaging","2025-07-24",{"date":173,"type":35},"2025-07-31",{"date":175,"type":35},"2024-10-02",{"date":177,"type":22},"2025-12",{"name":179,"class":42},"Singapore General Hospital",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":54,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":43},"100564607","transverse-versus-longitudinal-groin-incision-in-vascular-surgery-100564607","NCT06631378","Transverse Versus Longitudinal Groin Incision in Vascular Surgery","The Incidence of Surgical Site Complications in Transverse Versus Longitudinal Groin Incision in Vascular Surgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n• Patients undergoing vascular reconstruction with a groin incision\n\nExclusion Criteria:\n\n* Patients previously operated with a groin incision.\n* Patients undergoing operation due to trauma, bleeding, or pseudoaneurysm.\n* Patients operated within the first 24 hours of admission.\n* If it prior to the operation is deemed necessary with a muscleplasty.",{"count":188,"type":22},232,[56],"The purpose of the study is to examine whether incision type has an influence on the development of groin wound complications after operation in the groin in vascular surgery.\n\nThe main questions it aims to answer are:\n\nDoes a transverse incision in the groin lead to fewer surgical site complications than a longitudinal incision? Does a transverse incision lead to fewer readmissions, fewer reoperations, shorter length of hospital stay, and a lower amputation rate.\n\nParticipants will undergo vascular surgery in the groin with either a transverse or longitudinal incision. The incision type will be selected randomly.",[26,192],"Aneurysmal Disease",[194,195,196,197,198,199],"groin wound complications","surgical site complications","surgical site complication","vascular surgery","incision type","incision","2025-06-24",{"date":202,"type":35},"2025-06-27",{"date":204,"type":35},"2025-03-01",{"date":206,"type":22},"2027-07-01",{"name":208,"class":42},"Kolding Sygehus",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":18,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":43},"100266472","korean-vascular-intervention-society-multicenter-registry-study-on-outcomes-of-endovascular-therapy-in-lower-limb-artery-diseases-k-vis-ella-a-retrospective--prospective-observational-study-100266472","NCT02748226","Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)","Inclusion Criteria:\n\n* Retrospective data Patients who underwent or attempted endovascular treatment for symptomatic peripheral artery disease from January 2006 until IRB approval date\n* Prospective data\n\n  1. Age 20 years of older\n  2. Patients in the treatment or trying about symptomatic peripheral artery disease from IRB approval date\n  3. Symptomatic peripheral artery disease:\n\n     * Intermittent claudication (Rutherford category 1 to 3)\n     * Critical limb ischemia (Rutherford category 4 to 6)\n\nExclusion Criteria:\n\n1. Pregnant women or women with potential childbearing\n2. Moderate Alzheimer's disease, mental illness or neurological disease of more than those who can not understand the purpose of this clinical trials and Methods\n3. Life expectancy \\\u003C1 year due to comorbidity","20 Years",{"count":217,"type":22},12000,"1. Study design: multicenter retrospective and prospective observational study\n2. Study Cohort :\n\n   1. Retrospective cohort: This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals. Informed consent was waived by IRB.\n   2. Prospective cohort: This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals. Informed consent will be obtained prior to enrollment.\n3. Baseline clinical and lesion characteristics, procedural and post-procedural data, clinical outcomes, hemodynamic, and imaging follow-up data are investigated. Primary patency and target lesion revascularization rates of the total cohort and patient subgroups are evaluated. Risk factors of restenosis and target lesion revascularization are determined.",[26],"2025-04-28",{"date":222,"type":35},"2025-04-30",{"date":224,"type":35},"2013-09-30",{"date":226,"type":22},"2032-07-31",{"name":228,"class":42},"Yonsei University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":236,"targetDuration":238,"studyType":23,"phases":4,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100581430","effect-of-anticoagulant-and-antiplatelet-drug-intervention-on-postoperative-major-adverse-events-in-patients-with-padphase-ii-100581430","NCT06850207","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with Peripheral Arterial Disease：Phase II","Inclusion Criteria:\n\n* 1\\. History of PAD, or a history of intermittent claudication with an ankle\u002Fbrachial blood pressure ratio \\\u003C 0.9, or angiography-confirmed significant peripheral arterial stenosis (≥50%).\n\n  2\\. Underwent endovascular treatment for aortoiliac, femoral, popliteal, or infrapopliteal arteries.\n\n  3\\. No restrictions on endovascular treatment methods, including all internationally recognized devices and techniques used in real-world practice.\n\n  4\\. Agreed and signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. \\*\\*Patients with a history of stroke within the past month\\*\\* or a history of hemorrhagic or lacunar stroke.\n\n  2\\. Patients with a known ejection fraction \\\u003C 30% or severe heart failure with Class III\u002FIV symptoms.\n\n  3\\. Patients with non-cardiovascular diseases associated with poor prognosis(e.g., metastatic cancer) or interventions that increase the risk of adverse events in the study.\n\n  4\\. Patients with a history of allergies or known contraindications to drugs such as rivaroxaban or aspirin.\n\n  5\\. Patients with any known liver disease associated with coagulation disorders. 6. Pregnant or breastfeeding women, or women of childbearing potential who are sexually active and not using effective contraception.\n\n  7\\. Patients with known contraindications to any study-related procedures.",{"count":237,"type":22},6000,"12 Months","This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up by January 31, 2029). Patients will be grouped according to different combinations of anticoagulant and antiplatelet drugs used postoperatively for PAD. The types, dosages, and duration of postoperative anticoagulant and antiplatelet drug use will be recorded. Follow-up assessments will be conducted at 1 month, 6 months, and 12 months postoperatively to document the occurrence of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb Events (MALE) in the enrolled patients.",[26],[28,242,243],"Anticoagulant and Antiplatelet Drug","Adverse Events","2025-02-23",{"date":246,"type":35},"2025-02-27",{"date":248,"type":22},"2025-02-28",{"date":250,"type":22},"2029-01-31",{"name":252,"class":42},"Chengdu University of Traditional Chinese Medicine",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":260,"targetDuration":262,"studyType":23,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100574410","prospective-multicenter-single-arm-observational-study-to-confirm-the-safety-and-clinical-performance-of-the-oscar-peripheral-multifunctional-catheter-for-the-dilatation-of-lesions-in-the-femoral-popliteal-and-infrapopliteal-arteries-bio-oscar-first-100574410","NCT06758921","Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries (BIO-OSCAR First)","Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries","Inclusion Criteria:\n\n1. Subject ≥18 years old\n2. Subject has provided written informed consent\n3. Subject has Rutherford classification 2 to 6\n4. Reference vessel diameter ≥2 and ≤7 mm\n5. Target lesion(s) has stenosis \\>70% by visual assessment\n6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.\n\n   Above the knee (ATK) group:\n7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)\n8. At least one below-knee artery patent to the ankle\n9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.\n\n   Below the knee (BTK) group:\n10. Target lesions involve arteries below the tibial plateau\n11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications\n\nExclusion Criteria:\n\n1. Subject has a single target lesion that involves both ATK and BTK segments.\n2. Subject not suitable for receiving endovascular procedures of lower limb arteries.\n3. Prior planned major amputation in the target limb (i.e., above the ankle).\n4. Subject with previous bypass surgery of target vessel.\n5. History of any open surgical procedure within the past 30 days.\n6. Planned vascular surgery procedure within the next 30 days after the ATK and\u002For BTK procedure on the target limb.\n\n   Note: The inflow vessels can be treated on the day of the procedure.\n7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis).\n8. Subject under dialysis.\n9. Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached.\n10. Subject lacking capacity to provide informed consent.\n11. Subject under judicial protection, tutorship, or curatorship (for France only).",{"count":261,"type":22},200,"3 Days","The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.",[169,26],"2024-12-28",{"date":267,"type":35},"2025-01-06",{"date":269,"type":35},"2024-12-19",{"date":271,"type":22},"2026-01-20",{"name":273,"class":151},"Biotronik AG",16,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":54,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":43},"100563589","effects-of-virtual-reality-exercises-on-individuals-with-peripheral-artery-disease-100563589","NCT06618131","Effects of Virtual Reality Exercises on Individuals With Peripheral Artery Disease","Examination of the Effects of Virtual Reality Exercises on Lower Extremity Skin Temperature, Arterial Stiffness, Gait Parameters and Enjoyment of Exercise in Individuals With Peripheral Arterial Disease","Inclusion Criteria:\n\n* Being diagnosed with PAD\n* Being between 18-65 years of age\n* Ankle-brachial index less than 0.9\n* Not having a lower extremity injury or surgery that would prevent participation in the exercise program\n\nExclusion Criteria:\n\n* History of cardiovascular events less than 3 months before the start of the study\n* Uncontrolled severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)\n* Uncontrolled diabetes mellitus (glycemic index ≥ 290)\n* Critical Limb Ischemia\n* Balance Problems\n* Vertigo\n* History of epilepsy\n* Dementia\n* Chronic diseases that may be contraindications for exercise","65 Years",{"count":284,"type":22},24,[56],"The aim of this study is to investigate the effects of virtual reality exercises on lower extremity skin temperature, arterial stiffness, gait parameters and enjoyment of exercise in individuals with peripheral arterial disease.",[26],[289,290,291,292,293],"virtual reality","exercise","arterial stiffness","gait analysis","skin temperature","2024-09-26",{"date":296,"type":35},"2024-10-01",{"date":298,"type":22},"2024-10",{"date":300,"type":22},"2025-03",{"name":302,"class":42},"Dokuz Eylul University"]